Dergiler / GORM:Gynecology Obstetrics & Reproductive Medicine / 2001 / Cilt: 7 - Sayı: 1
Borderline epithelial ovarian tumors: Analysis of nineteen cases with an assessment of the impact of staging and treatment
- Sayfa
- 59–61
- DOI
- —
Özet
A.Ü.T.F. Kadın Hastalıkları ve Doğum ABD' da 1994-1999 yılları arasında borderline over tümörü (BOT) tanısı almış olan 19 olgu tedavi ve sağkalım özellikleri açısından değerlendirildi. Ortalama hasta yaşının 39.2 olduğu olgularda en sık rastlanan yakınmanın karın distansiyonu olduğu saptandı. Tüm hastalara cerrahi evrelendirme uygulandı. FIGO evrelemesine göre 15 olgu evre IA, bir olgu evre IB, bir olgu evre IC ve iki olgu evre IIIA idi. Postoperatif olarak, 19 olgudan onbirine cis-platin bazlı kemoterapi verildi ve iki olguya radyoterapi uygulandı. İzlemde hiçbir olguda rekürren hastalık saptanmadı. BOT'lü tüm hastalara cerrahi evrelendirme yapılmalıdır. Adjuvan tedavinin değerinin ortaya konması açısından daha ileri çalışmalara ihtiyaç vardır
Abstract
OBJECTIVE: To analyse treatment and survival characteristics of borderline ovarian tumors. STUDY DESIGN: Nineteen patients diagnosed as borderline ovarian tumors during the time period from 1994 to 1999 were evaluated. All the patients underwent surgical staging according to the FIGO 1987 classification. RESULTS: Mean age of patients was 39,2 years. The most frequent complication was abdominal distension, seen in 42,2% of the patients. Serous histologic tumor type was the most frequent and seen in twelve of the 19 patients. There were 15 cases with FIGO stage IA, one with stage IB, one with stage IC, and two with stage IIIA. Eleven of the 19 patients received cisplatin-based chemotherapy, two patients also received radiation therapy. During the follow-up period, none of the patients developed recurrent disease. CONCLUSION: Surgical staging should be done in all patients, and the usefullness of the adjuvant chemotherapy is to be investigated with extended studies. But it is obvious that multicentric studies are necessary to develop universally accepted optimal management of borderline ovarian tumors. (Gynecol Obstet Reprod Med 2001; 7:59-61)